Finding small development-stage biotech firms that contribute to biotechnology's limitless revolution of the biological sciences is difficult, but indispensable. Falling on firms that might have the science, the technological capability and the inspiration towards creating new diagnostics and treatments for severe diseases, is rewarding through improving lives.
Learning about Rubius Therapeutics (RUBY) has given us the impression . . .